vs
Side-by-side financial comparison of Hologic (HOLX) and TRINITY INDUSTRIES INC (TRN). Click either name above to swap in a different company.
Hologic is the larger business by last-quarter revenue ($1.0B vs $611.2M, roughly 1.7× TRINITY INDUSTRIES INC). TRINITY INDUSTRIES INC runs the higher net margin — 31.8% vs 17.1%, a 14.7% gap on every dollar of revenue. On growth, Hologic posted the faster year-over-year revenue change (2.5% vs -2.9%). Hologic produced more free cash flow last quarter ($215.2M vs $158.6M). Over the past eight quarters, Hologic's revenue compounded faster (1.5% CAGR vs -13.1%).
Hologic, Inc. is an American medical technology company primarily focused on women's health; it sells medical devices for diagnostics, surgery, and medical imaging.
Trinity Industries Inc. is an American industrial corporation that owns a variety of businesses which provide products and services to the industrial, energy, transportation and construction sectors.
HOLX vs TRN — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.0B | $611.2M |
| Net Profit | $179.1M | $194.2M |
| Gross Margin | 56.0% | 25.5% |
| Operating Margin | 22.6% | 54.9% |
| Net Margin | 17.1% | 31.8% |
| Revenue YoY | 2.5% | -2.9% |
| Net Profit YoY | -10.9% | 413.8% |
| EPS (diluted) | $0.79 | $2.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.0B | $611.2M | ||
| Q3 25 | $1.0B | $454.1M | ||
| Q2 25 | $1.0B | $506.2M | ||
| Q1 25 | $1.0B | $585.4M | ||
| Q4 24 | $1.0B | $629.4M | ||
| Q3 24 | $988.0M | $798.8M | ||
| Q2 24 | $1.0B | $841.4M | ||
| Q1 24 | $1.0B | $809.6M |
| Q4 25 | $179.1M | $194.2M | ||
| Q3 25 | $187.2M | $30.3M | ||
| Q2 25 | $194.9M | $14.1M | ||
| Q1 25 | $-17.4M | $22.1M | ||
| Q4 24 | $201.0M | $37.8M | ||
| Q3 24 | $178.6M | $31.4M | ||
| Q2 24 | $194.5M | $54.4M | ||
| Q1 24 | $169.9M | $23.7M |
| Q4 25 | 56.0% | 25.5% | ||
| Q3 25 | 55.6% | 31.1% | ||
| Q2 25 | 56.3% | 26.4% | ||
| Q1 25 | 37.5% | 24.3% | ||
| Q4 24 | 56.8% | 24.6% | ||
| Q3 24 | 56.4% | 21.2% | ||
| Q2 24 | 55.4% | 21.3% | ||
| Q1 24 | 53.3% | 20.3% |
| Q4 25 | 22.6% | 54.9% | ||
| Q3 25 | 22.6% | 26.1% | ||
| Q2 25 | 24.9% | 18.8% | ||
| Q1 25 | -0.7% | 17.0% | ||
| Q4 24 | 22.5% | 17.8% | ||
| Q3 24 | 23.3% | 15.3% | ||
| Q2 24 | 24.1% | 16.9% | ||
| Q1 24 | 20.7% | 14.2% |
| Q4 25 | 17.1% | 31.8% | ||
| Q3 25 | 17.8% | 6.7% | ||
| Q2 25 | 19.0% | 2.8% | ||
| Q1 25 | -1.7% | 3.8% | ||
| Q4 24 | 19.7% | 6.0% | ||
| Q3 24 | 18.1% | 3.9% | ||
| Q2 24 | 19.2% | 6.5% | ||
| Q1 24 | 16.7% | 2.9% |
| Q4 25 | $0.79 | $2.25 | ||
| Q3 25 | $0.84 | $0.37 | ||
| Q2 25 | $0.86 | $0.17 | ||
| Q1 25 | $-0.08 | $0.26 | ||
| Q4 24 | $0.87 | $0.34 | ||
| Q3 24 | $0.75 | $0.37 | ||
| Q2 24 | $0.82 | $0.65 | ||
| Q1 24 | $0.72 | $0.28 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.4B | $201.3M |
| Total DebtLower is stronger | $2.5B | — |
| Stockholders' EquityBook value | $5.2B | $1.1B |
| Total Assets | $9.2B | $8.4B |
| Debt / EquityLower = less leverage | 0.48× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.4B | $201.3M | ||
| Q3 25 | $2.2B | $66.3M | ||
| Q2 25 | $1.9B | $147.7M | ||
| Q1 25 | $1.6B | $94.9M | ||
| Q4 24 | $2.0B | $228.2M | ||
| Q3 24 | $2.3B | $222.4M | ||
| Q2 24 | $2.4B | $257.1M | ||
| Q1 24 | $2.2B | $118.8M |
| Q4 25 | $2.5B | — | ||
| Q3 25 | $2.5B | — | ||
| Q2 25 | $2.5B | — | ||
| Q1 25 | $2.5B | — | ||
| Q4 24 | $2.5B | — | ||
| Q3 24 | $2.5B | — | ||
| Q2 24 | $2.5B | — | ||
| Q1 24 | $2.6B | — |
| Q4 25 | $5.2B | $1.1B | ||
| Q3 25 | $5.0B | $1.0B | ||
| Q2 25 | $4.8B | $1.0B | ||
| Q1 25 | $4.6B | $1.1B | ||
| Q4 24 | $4.8B | $1.1B | ||
| Q3 24 | $5.1B | $1.1B | ||
| Q2 24 | $5.0B | $1.1B | ||
| Q1 24 | $4.8B | $1.0B |
| Q4 25 | $9.2B | $8.4B | ||
| Q3 25 | $9.0B | $8.9B | ||
| Q2 25 | $8.8B | $8.8B | ||
| Q1 25 | $8.5B | $8.7B | ||
| Q4 24 | $8.7B | $8.8B | ||
| Q3 24 | $9.2B | $8.8B | ||
| Q2 24 | $8.9B | $9.0B | ||
| Q1 24 | $8.7B | $9.1B |
| Q4 25 | 0.48× | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | 0.52× | — | ||
| Q1 25 | 0.55× | — | ||
| Q4 24 | 0.53× | — | ||
| Q3 24 | 0.49× | — | ||
| Q2 24 | 0.51× | — | ||
| Q1 24 | 0.53× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $229.9M | $177.4M |
| Free Cash FlowOCF − Capex | $215.2M | $158.6M |
| FCF MarginFCF / Revenue | 20.5% | 25.9% |
| Capex IntensityCapex / Revenue | 1.4% | 3.1% |
| Cash ConversionOCF / Net Profit | 1.28× | 0.91× |
| TTM Free Cash FlowTrailing 4 quarters | $1.0B | $314.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $229.9M | $177.4M | ||
| Q3 25 | $355.1M | $44.2M | ||
| Q2 25 | $343.3M | $61.6M | ||
| Q1 25 | $169.4M | $76.5M | ||
| Q4 24 | $189.3M | $201.6M | ||
| Q3 24 | $367.0M | $78.5M | ||
| Q2 24 | $405.8M | $241.5M | ||
| Q1 24 | $292.4M | $52.2M |
| Q4 25 | $215.2M | $158.6M | ||
| Q3 25 | $341.4M | $35.3M | ||
| Q2 25 | $330.5M | $52.9M | ||
| Q1 25 | $153.9M | $67.3M | ||
| Q4 24 | $172.5M | $180.1M | ||
| Q3 24 | $350.6M | $62.1M | ||
| Q2 24 | $385.3M | $230.2M | ||
| Q1 24 | $279.6M | $47.6M |
| Q4 25 | 20.5% | 25.9% | ||
| Q3 25 | 32.5% | 7.8% | ||
| Q2 25 | 32.3% | 10.5% | ||
| Q1 25 | 15.3% | 11.5% | ||
| Q4 24 | 16.9% | 28.6% | ||
| Q3 24 | 35.5% | 7.8% | ||
| Q2 24 | 38.1% | 27.4% | ||
| Q1 24 | 27.5% | 5.9% |
| Q4 25 | 1.4% | 3.1% | ||
| Q3 25 | 1.3% | 2.0% | ||
| Q2 25 | 1.3% | 1.7% | ||
| Q1 25 | 1.5% | 1.6% | ||
| Q4 24 | 1.6% | 3.4% | ||
| Q3 24 | 1.7% | 2.1% | ||
| Q2 24 | 2.0% | 1.3% | ||
| Q1 24 | 1.3% | 0.6% |
| Q4 25 | 1.28× | 0.91× | ||
| Q3 25 | 1.90× | 1.46× | ||
| Q2 25 | 1.76× | 4.37× | ||
| Q1 25 | — | 3.46× | ||
| Q4 24 | 0.94× | 5.33× | ||
| Q3 24 | 2.05× | 2.50× | ||
| Q2 24 | 2.09× | 4.44× | ||
| Q1 24 | 1.72× | 2.20× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
TRN
| Manufacturing | $296.5M | 49% |
| Leasing And Management | $234.8M | 38% |
| Maintenance Services Domain | $69.8M | 11% |
| Digital Logistics Services | $11.2M | 2% |
